In 1989, Dr. Robert Malone invented the platform technology that allowed mRNA to transfer into mammalian cells.
Dr. Malone's invention stabilized nucleic acid by packaging it in a liposome with a positive charge. A liposome is a lipid sac that can carry drugs or other substances like mRNA into tissues.
Lipid nanoparticles are new and improved delivery devices based on Malone's technology.
And these lipid nanoparticles are the foundation of our currently used experimental mRNA vaccines. These are widely used globally and even mandated in the United States.
However, the scientific literature has recognized the toxicity of these positively-charged lipid nanoparticles since 2010.
This 2010 study from Tel Aviv University showed that these lipid nanoparticles dramatically increased inflammatory markers in mice such as interleukins, interferons, TNF alpha, and Toll-Like receptors. Furthermore, inflammatory cytokines were elevated up to 75 times higher in the lipid treatment group than in the controls.
Dr. Kedmi warned, "These results suggest that careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics." See the last sentence of his abstract below.
Although Katalyn Kariko and others attempted to make the mRNA nucleic acid portion of the vaccine less inflammatory through studies published in 2005 and 2008, the inflammation produced by the lipid nanoparticles persisted, as Dr. Sonia Ndeupen explains in her introduction – first paragraph – in the link below.
Dr. Ndeupen of Thomas Jefferson University and colleagues recently published the results of a pre-print study that tested the inflammatory effects of positively-charged lipid nanoparticles (LNP) in mice. The researchers challenged the mice with various types of injections of these LNPs. Some were delivered intradermally - under the skin - while others were delivered intranasally.
The results were shocking.
The LNP inoculated mice developed rapid and visible signs of inflammation with significant elevations of inflammatory cytokines, including the signature ones, Interleukin 1 beta and Interleukin 6. In addition, thousands of genes involved in the inflammatory response were upregulated, including the CXCL series.
Mice are particularly "susceptible to intranasal inoculation of inflammatory compounds." Thus it was not surprising that 80% of those mice who received the highest intranasal doses of LNP suffered massive lung inflammation. Within hours, the lungs were visibly reddened and inflamed.
Moreover, 80% of those LNP inoculated mice died within 24 hours.
The scientists concluded, "Thus similar to skin inoculation, intranasal delivery of LNPs leads to massive inflammation. Furthermore, the LNPs' inflammatory properties are not site-specific; and show a fast diffusion, dispersion and distribution rate in the (other) tissues."
The researchers advised that it is highly likely "that intramuscular injection of the LNPs triggers similar inflammatory responses in muscle."
They warn, "However, further studies will be needed to determine the exact nature of the inflammatory responses triggered by the mRNA LNP vaccines in humans, and how much overlap there might be with the inflammatory signatures documented here for mice."
Further studies? Concerning our mRNA vaccines already in widespread use, the horse may already have left the barn. I know no other studies the vaccine manufacturers are interested in conducting. They have been granted immunity from lawsuits, so why would they conduct further tests?